After two days of excellent presentations, we are now ready to let our expert Panel address the provocative question of rodent liver nodules-significance to human cancer risk? But before we begin this forum, I would like to make several comments.
The Society is sponsoring this meeting for a very practical reason. A large proportion of our membership has the responsibility for interpreting cellular changes in laboratory animals. The results of these studies are used in assessing human risk.
Nomenclature or terminology associated with pathologic cellular changes is not a trivial matter and has great importance in these applied rather than basic research efforts. Hence, we are acutely aware that combining hyperplasia and neoplasia into one diagnostic term such as neoplastic nodule, commonly establishes these lesions as cancer in the minds of the non-biologists who challenge the results of safety studies from a legal or social interest point of view.
Based on what we have heard over the past two days, it would seem that most neoplastic nodules do have the capacity to regress. We as toxicologic pathologists are fully aware of ubiquitous occurrence of these experimentally induced lesions in rodents. We also have over 30 years of rodent testing experience to call upon to more objectively evaluate the clinical significance of these findings in the test species as well as less objective evidence from human adverse reaction files and epidemiological studies.
The question then becomes: is the data available from non-published, experience generated sources sufficient to override the con-Presented at the International Symposium of the Society of Toxicologic Pathologists. Reston. Virginia. May 10-12. 1982. 206 cern that a select few of the experimentally induced liver nodules do not regress from a benefit to risk point of view? Or is the concern that even if one rodent neoplastic nodules does not regress, is this sufficient cause to consider all neoplastic nodules as indicators of cancer in the context of extrapolation to humans?
Now to accomplish this, the membership of our panel was designed to include representatives of the academic, industrial and regulatory communities. We look to the academic experimental pathologists to provide the basis for the applied research aspects of toxicologic pathology, but realize there is little chance for them to become intimately involved in the practical day to day interpretive problems of safety assessment experiments. We look to the industrial pathologists to share the historical experiences of many years of safety testing, but realize that such information may be considered by outsiders to be suspect because of commercial affiliation. And finally we look to the regulatory scientists to apply these data in a risk/benefit context, but recognize the legislative, legal and social pressures which are imposed upon these decisions.
We believe the debatable biological problems associated with safety assessment will be most intelligently resolved through advisory panels incorporating these three points of view. Efforts in the past to resolve such issues by isolated expert efforts from anyone of the three areas has only polarized and intensified disciplinary bias and left society rightly confused.
Maybe it is appropriate to refer to the anatomical configuration of our Panel today as a triad and within the context of our subject matter-a hepatic triad. One might fantasize that the academic interest represent the he-
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patic artery carrying oxygenated blood to sustain future development of the liver. Industry is probably best represented by the hepatic vein which disseminates the usable products of the liver. The regulatory agencies must then present the bile ducts separating the desirable from non-desirable products, but also involved in reviewing past issues by a process known as enterohepatic recirculation. I would strongly urge those of you in attendance to let your views be known when the discussion is opened to the floor. Please use the microphones for your comments or questions, identify yourself for the benefit of the transcriptions which will be used in the publication of the proceedings and please keep in mind the Panel's objectives when you formulate your questions or comments. I know this subject can invoke emotional responses, but I hope we can concentrate on the major issues.
I would now like to introduce our Panel Chairman and Moderator for this morning's session, Dr. Tom Murchison. Dr. Murchison is a member of the American College of Veterinary Pathologists, has had extensive experience with the practical application of toxicologic pathology and was a member of the original conference which addressed rodent liver morphological descriptions and the definition of morphologic terms that we are debating at this time. Dr. Murchison.
